CONTENTS目錄1二零二一╱二零二二年年報 衍生集團（國際）控股有限公司Financial Highlights財務摘要2Definitions釋義3Corporate Information公司資料7Corporate Structure公司架構9Chairman’s Statement主席報告10Management Discussion and Analysis管理層討論及分析15Directors and Senior Management董事及高級管理層26Environmental, Social and Governance Report環境、社會及管治報告34Corporate Governance Report企業管治報告85Report of the Directors董事會報告112Independent Auditors’ Report獨立核數師報告132Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表141Consolidated Statement of Financial Position綜合財務狀況表143Consolidated Statement of Changes in Equity綜合權益變動表145Consolidated Statement of Cash Flows綜合現金流量表146Notes to the Consolidated Financial Statements綜合財務報表附註148Five Years Financial Summary五年財務概要272 FINANCIAL HIGHLIGHTS財務摘要2HIN SANG GROUP (INTERNATIONAL) HOLDING CO. LTD. Annual Report 2021/2022Increase/(Decrease)2021/2022年2020/2021年增加╱（減少）% Operating results (HK$’000)經營業績（千港元）Revenue收入120,546119,4411,1050.9Gross profit毛利69,07568,7932820.4Loss for the year年內虧損(13,105)(36,846)(23,741)(64.4)Profitability (%)盈利能力(%)Gross profit margin毛利率57.357.6(0.3)(0.5)Net profit margin純利率(10.9)(30.8)19.964.6Return on equity股本回報率(4.3)(11.5)7.262.6Return on total assets總資產回報率(1.9)(5.2)3.363.5Liquidity流動資金Current ratio (time)流動比率（倍）0.30.4(0.1)(25.0)Quick ratio (time)速動比率（倍）0.20.3(0.1)(33.3)Inventory turnover (days)存貨週轉（天數）167.9110.957.051.4Trade receivables turnover (days)貿易應收款項週轉 （天數）27.433.7(6.3)(18.7)Trade payables turnover (days)貿易應付款項週轉 （天數）68.878.9(10.1)(12.8)Per share data每股數據Loss per share每股虧損 – Basic (HK cents) – 基本（港仙）(1.09)(2.93)(1.84)(62.8) – Diluted (HK cents) – 攤薄（港仙）(1.09)(2.93)(1.84)(62.8)Dividend per share每股股息 – Interim (HK cents) – 中期（港仙）–––– – Final (HK cents) – 末期（港仙）–––– DEFINITIONS釋義3二零二一╱二零二二年年報 衍生集團（國際）控股有限公司In this annual report, unless the context otherwise requires, the following terms and expressions shall have the meanings set out below.“Audit Committee”the audit committee of the Company“Board”the board of Directors“Brand Development and Management Segment”the business segment in which the Group purchases primarily personal care products from the brand proprietors and manages and develops the brand of such products“BVI”the British Virgin Islands“Company”Hin Sang Group (International) Holding Co. Limited, 衍生集團(國際)控股有限公司, an exempted company incorporated with limited liability in the Cayman Islands on 28 October 2010“Controlling Shareholder(s)”has the meaning ascribed thereto under the Listing Rules and, in the context of the Company, means each of Mr. Pang, Mrs. Pang and Genwealth“Director(s)”the directors of the Company“Fullshare”Fullshare Holdings Limited, 豐盛控股有限公司, a company incorporated in the Cayman Islands with limited liability whose issued shares are listed on the Stock Exchange (stock code: 607)“Fullshare Group”Fullshare and its subsidiaries於本年報中，除文義另有所指外，下列詞彙及詞語具以下的涵義。「審核 委員會」指 本公司審核委員會「董事會」指 董事會「品牌開發 及管理 分部」指 本集團主要自品牌擁有人採購個人護理產品以及管理及開發該等產品之品牌的業務分部「英屬處女 群島」指 英屬處女群島「本公司」指 衍生集團（國際）控股有限公司，一間於2010年10月28日在開曼群島註冊成立之獲豁免有限公司「控股股東」指 具上市規則所賦予之涵義，就本公司而言，分別指彭先生、彭太太及衍富「董事」指 本公司董事「豐盛」指 豐盛控股有限公司，一間於開曼群島註冊成立之有限公司，其已發行股份於聯交所上市（股份代號：607）「豐盛集團」指 豐盛及其附屬公司 DEFINITIONS釋義4HIN SANG GROUP (INTERNATIONAL) HOLDING CO. LTD. Annual Report 2021/2022「衍富」指 衍富集團控股有限公司，一間於2010年10月5日在英屬處女群島註冊成立之有限公司，其已發行股份由彭先生及彭太太分別擁有90%及10%，根據上市規則為本公司的控股股東「GMP」指 「良好生產規範」乃全球藥品生產行業使用之質量保證方法，以確保產品根據適當質量標準貫徹生產及監控。香港與大部分其他國家一樣，已採納世界衛生組織（世衛）頒佈之GMP指引「本集團」指 本公司及其附屬公司「健康分部」指 本集團在香港及中國從事向母嬰提供中醫保健相關服務之業務分部「衍豐集團」指 衍豐集團（國際）控股有限公司，一間於2016年7月7日於香港成立之合營公司，由本公司擁有51%權益及Five Seasons VIII Limited（豐盛之全資附屬公司）擁有49%權益「衍生控股」指 衍生集團控股有限公司，一間於2006年9月11日在英屬處女群島註冊成立之有限公司及由本公司直接全資擁有“Genwealth”Genwealth Group Holding Company Limited (衍富集團控股有限公司), a company incorporated with limited liability on 5 October 2010 in the BVI, the issued shares of which are owned as to 90% by Mr. Pang and 10% by Mrs. Pang, a controlling shareholder of the Company under the Listing Rules “GMP”“Good Manufacturing Practice” is a quality assurance approach used by drug manufacturing industry worldwide to ensure that products are consistently produced and controlled according to appropriate quality standards. Hong Kong, like most other countries, has adopted the GMP guidelines promulgated by the World Health Organisation (WHO)“Group”the Company and its subsidiaries“Healthcare Segment”the business segment in which the Group engages in providing Chinese medical healthcare related services which targets for mothers and children in Hong Kong and the PRC“Hin Feng Group”Hin Feng Group (International) Holding Company Limited 衍豐集團(國際)控股有限公司, a joint venture company established in Hong Kong on 7 July 2016, owned as to 51% by the Company and as to 49% by Five Seasons VIII Limited (a wholly-owned subsidiary of Fullshare)“Hin Sang Holding”Hin Sang Group Holding Limited (衍生集團控股有限公司), a company incorporated with limited liability on 11 September 2006 in the BVI and directly wholly-owned by the Company